drugset / Trial / NCT05785611

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611

Phase 3 Active not recruiting 495 enrolled Alfasigma S.p.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.

Timeline

Start
2023-04-05
Primary completion
2024-09-04
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Filgotinib Small molecule 100 mg Oral
Subject Filgotinib Small molecule 200 mg Oral

Indications